Citi Pharma reports higher quarterly profit and EPS

Financial Result

Citi Pharma Limited reported consolidated revenue of Rs. 3.514 billion and profit attributable to owners of Rs. 248.792 million for the quarter ended September 30, 2026. Compared with the same quarter last year, revenue, operating profit, net profit and EPS were higher.

Key Findings

  • Revenue increased to Rs. 3,514,442,888 from Rs. 3,370,247,671.
  • Operating profit increased to Rs. 511,162,226 from Rs. 420,355,037.
  • Profit attributable to owners rose to Rs. 248,792,484 from Rs. 203,690,873.
  • EPS increased to Rs. 1.09 from Rs. 0.89.

Financial Performance

MetricPreviousQuarter ended September 30, 2025CurrentQuarter ended September 30, 2026Change
Sales - net3,370,247,6713,514,442,888+4.3%
Gross profit518,973,622674,262,488+29.9%
Operating profit420,355,037511,162,226+21.6%
Profit attributable to owners of the Holding Company203,690,873248,792,484+22.1%
Earnings per share - basic and diluted (Rupees)0.891.09+22.5%
Financial charges(121,191,504)(100,672,701)-16.9%
Cash and bank balances208,822,019270,807,545+29.7%
Short term borrowings2,869,594,9572,856,035,136-0.5%
⚡

Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.

More CPHL announcements

Built for PSX investors

Every filing.Summarised.

Key findings from every PSX announcement, right beside live prices and your portfolio.

Investify company announcements with result figures and filing highlights
Investify announcement summary with key findings from a PSX filing